Stocks Health care CTNM
NASDAQ · Health careContineum Therapeutics, Inc. (CTNM)
It posted a net loss of $63.5M. In fiscal 2025 capital spending exceeded operating cash flow by $55.5M. At September 30, 2026 it held $75.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Contineum Therapeutics, Inc.
- Net worth
- Contineum Therapeutics, Inc. has a market value (market cap) of $387.5M at the latest share price, and shareholders' equity of $245.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0 (-100.0% year on year), with a net loss of $42.3M.
- Cash flow
- In fiscal 2025 operations used $55.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Contineum Therapeutics, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Contineum Therapeutics, Inc. does
Contineum Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTNM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$60M | -$2.17 | -$55.5M |
| 2024 | $0 | -$42.3M | -$2.18 | -$33.4M |
| 2024 | $50M | $22.7M | $0.08 | $18.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Contineum Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 5, 2026Passive stake (5% or more) SCHEDULE 13G
- November 3, 2026
- November 3, 2026
- October 28, 2026Passive stake (5% or more) SCHEDULE 13G
- October 22, 2026Passive stake (5% or more) SCHEDULE 13G
- September 14, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026
- July 30, 2026
Insider trades
What the people running Contineum Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $41.1K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Stengone Carmine N.CEO and President, Director | Exercised options | 2,500 | $2.5K |
| September 8, 2026 | Stengone Carmine N.CEO and President, Director | Soldpre-planned (10b5-1) | 2,500 | $41.1K |
| August 3, 2026 | Stengone Carmine N.CEO and President, Director | Exercised options | 2,500 | $2.5K |
| August 3, 2026 | Stengone Carmine N.CEO and President, Director | Soldpre-planned (10b5-1) | 2,500 | $40K |
| July 9, 2026 | Lorrain Daniel S.Chief Scientific Officer | Exercised options | 25 | $25.3 |
| July 9, 2026 | Lorrain Daniel S.Chief Scientific Officer | Soldpre-planned (10b5-1) | 25 | $400 |
| July 8, 2026 | Lorrain Daniel S.Chief Scientific Officer | Exercised options | 1,015 | $1K |
| July 8, 2026 | Lorrain Daniel S.Chief Scientific Officer | Soldpre-planned (10b5-1) | 1,015 | $16.2K |
Who owns CTNM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 7.9% | November 5, 2026 |
| Janus Henderson Group PLC13G, passive | 7.9% | February 17, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 7.14% | August 14, 2026 |
| Johnson & Johnson Innovation - JJDC, Inc.13G, passive with 1 related filers | 5.6% | November 6, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 5.1% | October 28, 2026 |
| Trails Edge Capital Partners, LP13G, passive with 2 related filers | 5.1% | October 22, 2026 |
| Jérôme G. Pfund13G, passive with 1 related filers | 5% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 102 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 2,841,334 | 0 |
| Jupiter Topco LLC | 2,734,836 | new |
| BlackRock, Inc. | 2,064,345 | +1,395,222 |
| Johnson & Johnson | 1,979,173 | 0 |
| Franklin Resources Inc | 1,839,227 | 0 |
| Balyasny Asset Management L.P. | 1,522,793 | -162,842 |
| Vanguard Capital Management LLC | 1,321,356 | +107,183 |
| Perceptive Advisors LLC | 1,255,592 | 0 |
| Fmr LLC | 1,040,130 | +225,259 |
| Millennium Management LLC | 931,709 | -603,740 |
| Great Point Partners LLC | 921,481 | +121,283 |
| Longaeva Partners L.P. | 812,757 | +80,669 |
| Ikarian Capital, LLC | 807,874 | 0 |
| Sectoral Asset Management Inc | 727,587 | 0 |
| Geode Capital Management, LLC | 693,188 | +411,150 |
| Hhlr Advisors, Ltd. | 669,337 | 0 |
| Red Tree Management, LLC | 638,158 | 0 |
| Versant Venture Management, LLC | 542,628 | 0 |
| Goldman Sachs Group Inc | 497,255 | +190,147 |
| Boxer Capital Management, LLC | 494,000 | 0 |
Insiders
3 insiders reported holding 161,380 shares in total, about $1.7M at the last price.
| Holder | Shares |
|---|---|
| Lorrain Daniel S.Chief Scientific Officer | 135,202 |
| Stengone Carmine N.CEO and President, Director | 17,217 |
| Watkins TimCMO & Head of Development | 8,961 |
Questions about CTNM
What does Contineum Therapeutics, Inc. do?
Contineum Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CTNM. Its shares trade on NASDAQ under the ticker CTNM.
What is Contineum Therapeutics, Inc.'s net worth?
Contineum Therapeutics, Inc. has a market value (market cap) of $387.5M at the latest share price, and shareholders' equity of $245.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Contineum Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $63.5M.
When did Contineum Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Contineum Therapeutics, Inc.'s next earnings report?
Contineum Therapeutics, Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CTNM with
Follow CTNM
Get an email when Contineum Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Contineum Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.